Best Cell & Gene Therapy CDMOs in South Korea
· updated as new inspection, certificate, and trial data enters the platform
6
CDMOs tracked
5
Fully scored
1
With FDA records
1
FDA inspections
Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.
For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).
FDA inspection outcomes across these CDMOs: 1 NAI (no action), 0 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (1).
Last updated 2026-08-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
LB
Lotte Biologics
Incheon, KR · Syracuse, NY
|
83.7 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 2 |
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | Available | 0 programs |
| 3 |
HX
Helixmith
Seoul, KR
|
59.0 | — | — | — | 0 programs |
| 4 |
GC
Green Cross Cell
Yongin, KR
|
56.5 | — | — | — | 0 programs |
| 5 |
CH
CHA Medical & Bio Group
Seongnam, KR
|
56.5 | — | — | — | 0 programs |
| — |
CdmoGen Co., Ltd.
Cheongju, South Korea
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Cell & Gene Therapy CDMO
Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.
What has driven South Korea's rise as a biologics manufacturing hub?
South Korea's biologics CDMO growth (2015-present) has been driven by three factors: (1) Samsung Biologics' massive Songdo capacity build (Plants 1-5 total >600,000L mammalian cell culture, one of the largest single-city concentrations of biologics capacity globally); (2) Celltrion's biosimilar-driven commercial capacity, exported globally; (3) national policy focus on biopharmaceutical export as a strategic industry. Korean CDMOs supplying US and EU markets typically hold MFDS + FDA + EMA certifications concurrently — the Signal Score's Quality Compliance pillar captures all three. For biologics programs specifically, South Korea offers commercial-scale capacity availability that is genuinely scarce in the US and EU.
How do Samsung Biologics and Celltrion compare on CDMO offerings?
Samsung Biologics operates primarily as a contract manufacturer (CDMO) with dedicated commercial biologics capacity at Songdo; Celltrion combines internal biosimilar development with CDMO services, with significant capacity dedicated to their own commercial products. For pure CDMO engagements, Samsung Biologics is typically the more scale-available option; for programs where biosimilar development experience is a plus, Celltrion's integrated model can add value. Both hold FDA and EMA certifications. Cross-check with the biologics CDMO ranking for the broader Korean biologics landscape and individual profile pages for facility-level detail.
South Korean CDMOs supplying US and EU markets — regulatory considerations
South Korean CDMOs supplying US and EU markets need active FDA and EMA GMP certifications on the specific facility. Both regulators have inspection experience with major Korean biologics sites, and inspection outcomes have generally been favorable. For programs supplying UK specifically, post-Brexit MHRA acceptance of MFDS + EMA-recognized inspections has continued under transitional arrangements — sponsors should confirm current MHRA policy at RFP stage. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so Korean CDMOs with cross-jurisdictional posture rank higher on this pillar than domestic-market-only competitors.
Cell & Gene Therapy CDMOs — Frequently Asked Questions
Who are the top Cell & Gene Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Cell & Gene Therapy CDMOs include Lotte Biologics, SK pharmteco, Helixmith. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Cell & Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 1 Cell & Gene Therapy CDMO with FDA inspection records and 0 EMA/MHRA GMP certificates across the group.
What should I look for in a cell and gene therapy CDMO?
Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.
How many cell and gene therapy CDMOs does CDMO Signal track?
109 CDMOs are tracked as cell or gene therapy manufacturers — the union of cell therapy, AAV, lentiviral, adenoviral, and gene therapy-tagged CDMOs. This is the broadest advanced-therapy candidate list on our platform.
Related modalities